12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Innate Pharma (NASDAQ:IPHA), Ayala Pharmaceuticals (NASDAQ:AYLA), HTG Molecular Diagnostics (NASDAQ:HTGM), KalVista Pharma (NASDAQ:KALV), Nexalin Technology (NASDAQ:NXL), 180 Life Sciences (NASDAQ:ATNF), Surrozen (NASDAQ:SRZN), Conformis (NASDAQ:CFMS), Invacare (NYSE:IVC), Cosmos Health (NASDAQ:COSM), Soligenix (NASDAQ:SNGX), Aptinyx (NASDAQ:APTX)

Gainers

  • 180 Life Sciences ATNF stock rose 75.8% to $2.18 during Tuesday’s pre-market session. The company’s market cap stands at $4.4 million.
  • HTG Molecular Diagnostics HTGM stock moved upwards by 51.93% to $4.71. The market value of their outstanding shares is at $4.8 million.
  • Invacare IVC shares rose 42.82% to $0.59. The market value of their outstanding shares is at $22.2 million.
  • Nexalin Technology NXL shares moved upwards by 22.91% to $0.96. The market value of their outstanding shares is at $6.9 million.
  • Innate Pharma IPHA stock rose 14.23% to $3.21. The market value of their outstanding shares is at $257.4 million.
  • KalVista Pharma KALV stock moved upwards by 13.5% to $5.8. The market value of their outstanding shares is at $142.7 million.

Losers

  • Ayala Pharmaceuticals AYLA shares decreased by 13.8% to $0.35 during Tuesday’s pre-market session. The company’s market cap stands at $5.2 million.
  • Surrozen SRZN shares decreased by 11.31% to $0.47. The market value of their outstanding shares is at $13.9 million.
  • Cosmos Health COSM stock decreased by 10.16% to $5.75. The company’s market cap stands at $44.6 million.
  • Soligenix SNGX stock fell 10.12% to $0.58. The market value of their outstanding shares is at $25.0 million.
  • Aptinyx APTX shares declined by 8.37% to $0.31. The market value of their outstanding shares is at $20.9 million.
  • Conformis CFMS shares decreased by 8.11% to $3.4. The company’s market cap stands at $25.5 million.
    See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.



Image and article originally from www.benzinga.com. Read the original article here.